Topic transfection

News transfection

• Photoactivable bioluminescent probe

  A group of scientists led by Bengang Xing, at Nanyang Technological University, Singapore, in collaboration with Zhen Cheng and colleagues at Stanford University Medical Centre, California, have developed a photoactivable bioluminescent probe for imaging luciferase activity in live cells. Firefl more

• Xantos Biomedicine and QIAGEN AnnounceCo-Marketing Agreement for RNAi Library with High-Content Cellular Screening System

  Xantos Biomedicine AG and QIAGEN N.V. announced their partnership for co-marketing QIAGEN's proprietary TOM-amidite chemistry based genome-wide RNAi products with Xantos' automated cell-based screening platform, XantoScreen(TM). By combining the capabilities of both companies' platforms customers wi more

• ALTANA Pharma and Atugen Renew Target Validation and License Agreement

  Atugen AG announced that it has renewed its non-exclusive Target Validation and License Agreement with ALTANA Pharma AG for another year. The agreement gives Altana the right to have molecular targets validated by Atugen's discovery team, utilizing a number of proprietary knockdown tools and transfe more

White papers transfection

• Efficient Transfection of Primary Human Skeletal Myoblasts Using FuGENE® HD Transfection Reagent
  

  Transfection of cells is one of the main techniques used to influence gene expression. Most primary cells and human skeletal myoblasts (SkMC) in particular are very difficult to transfect, whereas for cell lines such as C2C12, many suitable transfection reagents and protocols are available. Few publications report successful transfection of human primary myoblasts using non-viral systems [1,2,3]. These methods include cationic lipids such as phosphono­lipids, electroporation, and a combination of liposome and adenoviral associated proteins. But transfection efficiency is low and often is a compromise between toxicity of the reagents and transfection efficiency. more

• Enabling Cancer Research with FuGENE® HD Transfection Reagent
  

  A major problem in some areas of cancer research is the difficulty of transfecting a significant number of the cells of interest, while minimizing the cytotoxic or other off-target effects of the transfection event itself. It is well-known that the use of some transfection reagents results in high levels of expression of the gene of interest in surviving cells, but also in high levels of cell death or other cellular alterations. FuGENE® HD Transfection Reagent overcomes these problems, results in high ­levels of transfection in many cancer cell lines, and thus enables researchers to conduct experiments that have previously not been possible. more

• Efficient Transfection of Neuroblastoma Cell Lines Using FuGENE® HD Transfection Reagent
  

  Efficient transfection of cells is a prerequisite for genetic manipulation. However, many cell lines remain hard to transfect with established protocols, hampering consecutive analysis. Here, we compare three different methods (FuGENE® HD Transfection Reagent, transfection reagent L, and calcium phosphate) for the transfection of neuroblastoma cell lines. We show that FuGENE® HD Transfection Reagent is able to transfect all of these cell lines with high efficiency for further analysis. more

Websites transfection